CA224 (Compound 1) 是一种选择性、具有口服活性的 Cdk4–cyclin D1 抑制剂,IC50 值为 6.2 µM,可诱导细胞凋亡 (apoptosis),并具有抗肿瘤活性。
产品编号: MS-P35585 纯度: 99.94% CAS No.: 883561-04-4 分子式: C24H22N2O 分子量: 354.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

CA224 (Compound 1) 是一种选择性、具有口服活性的 Cdk4–cyclin D1 抑制剂,IC50 值为 6.2 µM,可诱导细胞凋亡 (apoptosis),并具有抗肿瘤活性。

生物实验数据

生物活性 CA224 (Compound 1) is a selective, orally active Cdk4–cyclin D1 inhibitor with an IC50 value of 6.2 µM that induces apoptosis and exhibits antitumor activity.
IC50 & Target CDK4-CyclinD1:6.2 μM, CDK2-CyclinA:521 μM
体外研究
(In Vitro)

CA224 (Compound 1) (48 h) shows antiproliferation activity against human cancer cell lines.
CA224 (18-48 h) blocks the growth of cancer cells at G0/G1 and G2/M phase of the cell cycle, and selectively kills SV40 large T-antigen transformed normal mouse embryonic liver cells (BNL SV A.8).
CA224 (0-4 µM, 30 min) inhibits tubulin polymerization and enhances the depolymerization of stabilized tubulin protein.
CA224 (0-72 h) induces cell apoptosis in cancer cells.
CA224 (10 μM) shows 50%, 14%, 51% and 19% inhibition of CYP3A4, CYP2D6, CYP2C9, and CYP2C19, respectively.

Cell Proliferation Assay

Cell Line: LS174T, PC-3, MiaPaCa, A549, Calu-1, NCI-H460, NCI-H1299, NCI-H358, BNL CL2 and BNL SV A.8
Concentration:
Incubation Time: 48 h
Result: Showed antiproliferation activity with IC50 values of 3.5, 6.2, 4.0, 3.5, 11.5, 2.0, 2.5, 2.2, 2.6 and 3.8 uM against LS174T, PC-3, MiaPaCa, A549, Calu-1, NCI-H460, NCI-H1299, NCI-H358, BNL CL2 and BNL SV A.8, respectively.

Cell Cycle Analysis

Cell Line: A549, NCI-H1299, NCI-H358, BNL CL2, BNL SV A.8 and Calu-1
Concentration: IC50 concentration (IC70 for Calu-1)
Incubation Time: 24 h for A549, NCI-H1299 and Calu-1, 18 h for NCI-H358, 48 h for BNL CL2 and BNL SV A.8
Result: Induced a profound block at G2/M in A549 and NCI-H1299 cells. Maintained nocodazole- and paclitaxel-induced G2/M block in NCI-H358 cells. Exhibited prominent G2/M arrest in BNL CL2 cells. 31% of cells were detected in sub-G1 phase (control: 0%) in BNL SV A.8 cells. Retained the G0/G1 block in serum-starved p53-null Calu-1 cells.

Western Blot Analysis

Cell Line: A549 and LS174T
Concentration: IC50 concentration; 1, 2, 3 and 4 µM for tubulin polymerization
Incubation Time: 24 h; 30 min for tubulin polymerization in A549 cells
Result: Induced p53, p21, and p27. Downregulated cyclin B1 and Cdk1. Inhibited tubulin polymerization in a dose-dependent manner and resulted in accumulation of unassembled tubulin in the supernatant.

Apoptosis Analysis

Cell Line: A549, NCI-H460, NCI-H358, and NCI-H1299
Concentration: IC50 and IC70 concentration
Incubation Time: 24, 48 and 72 h
Result: Induces apoptotic cell death in a dose- and time-dependent manner.
体内研究
(In Vivo)

CA224 (Compound 1) (100 mg/kg; i.p.; once a day for 9 days) shows significant tumor growth inhibition without obvious toxicity.

Animal Model: The severe combined immunodeficient (SCID) mouse, lacking both T and B immune cells. Male mice weighing 18−25 g, 6−8 weeks of age for subcutaneous injection of HCT-116, female mice weighing 15−24 g, 6−8 weeks of age for subcutaneous injection of NCI-H460
Dosage: 100 mg/kg
Administration: Intraperitoneal injection, once a day for 9 consecutive days
Result: Showed significant tumor growth inhibition in both HCT-116 and NCI-H460 tumor models without significant bodyweight loss.
Animal Model: BALB/c mice
Dosage: 10 mg/kg (oral administration) or 1.0 mg/kg (intravenous injection)
Administration: Oral or intravenous injection (Pharmacokinetics Analysis)
Result: Pharmacokinetics parameters determined for CA224 after IV and PO administration.
Parameter IV (1 mg/kg) Oral (10 mg/kg)
t1/2,β (h) 0.33 1.16
AUC0-t (ng·h/mL) 187 172
AUC0-∞ (ng·h/mL) 189 182
Cmax (ng/mL) 371 190
Vd (L/Kg) 2.52 nd
Vdss (L/Kg) 1.76 nd
CL (mL/min/kg) 88.3 nd
Bioavailability - 9.6%
Time points considered
for t1/2,β calculation
0.5-2 h 1-4 h
性状 固体
颜色 White to off-white

化学信息

分子量 354.44
分子式 C24H22N2O
CAS No. 883561-04-4

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (282.14 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.8214 mL14.1068 mL28.2135 mL70.5338 mL
5 mM0.5643 mL2.8214 mL5.6427 mL14.1068 mL
10 mM0.2821 mL1.4107 mL2.8214 mL7.0534 mL
15 mM0.1881 mL0.9405 mL1.8809 mL4.7023 mL
20 mM0.1411 mL0.7053 mL1.4107 mL3.5267 mL
25 mM0.1129 mL0.5643 mL1.1285 mL2.8214 mL
30 mM0.0940 mL0.4702 mL0.9405 mL2.3511 mL
40 mM0.0705 mL0.3527 mL0.7053 mL1.7633 mL
50 mM0.0564 mL0.2821 mL0.5643 mL1.4107 mL
60 mM0.0470 mL0.2351 mL0.4702 mL1.1756 mL
80 mM0.0353 mL0.1763 mL0.3527 mL0.8817 mL
100 mM0.0282 mL0.1411 mL0.2821 mL0.7053 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础